Table 2. The changes in FMA, MBI, and sEMG level (mV) in the treatment group and control group in weeks 0, 4 and 8.
| Treatment group (n=11) |
Control group (n=12) |
|
|---|---|---|
| Barthel Index (0–100) | ||
| Week 0 | 38.8±7.7a | 37.5±5.9b |
| Week 4 | 44.1±9.8 | 40.9±11.5 |
| Week 8 | 65.5±9.5ae | 50.1±11.8be |
| Fugl-Meyer assessment (0–34) | ||
| Week 0 | 22.5±5.1c | 21.1±4.1d |
| Week 4 | 25.1±7.5 | 24.4±5.4 |
| Week 8 | 29±3.3cf | 27.8±5.5df |
| sEMG level (μV) of gastrocnemius | ||
| Week 0 | 21.8±6.9 | 19.9±7.1 |
| Week 4 | 15.8±7.8g | 26.8±9.1g |
| Week 8 | 14.1±7.7h | 29.9±8.4h |
Results are presented as the mean ± SD. a,b,c,dp<0.05, self-matching test for MBI and FMA, compared before and 8 weeks later. e,fp<0.05, comparison of MBI and FMA between the treatment and control groups at week 8. g,hp<0.05, comparison of the sEMG levels (μV) of the gastrocnemius between treatment and control groups at weeks 4 and 8.